Clinical importance of assessment of type 2 diabetes mellitus with visceral obesity. A Japanese perspective

Current Diabetes Reviews

Volumn 8, Issue 2, 2012, Pages 84-91

  Kishida, Ken ^a   Funahashi, Tohru ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Insulin; Obesity; Stratification; Visceral adiposity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; DULOXETINE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; MAZINDOL; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RIMONABANT; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ADIPOSE TISSUE; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BEHAVIOR MODIFICATION; BLOOD GLUCOSE MONITORING; BLOOD VESSEL INJURY; BODY FAT DISTRIBUTION; BREAST CANCER; CALORIC RESTRICTION; CLINICAL ASSESSMENT; COLON CANCER; COMORBIDITY; DYSLIPIDEMIA; ECHOGRAPHY; GASTRIC BANDING; GASTROPLASTY; GLYCEMIC CONTROL; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSOMNIA; INSULIN SENSITIVITY; JAPANESE; NARCOLEPSY; NIGHTMARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PERIODIC LIMB MOVEMENT DISORDER; PHYSICAL ACTIVITY; POSTPRANDIAL STATE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RESTLESS LEGS SYNDROME; SLEEP APNEA SYNDROME; SLEEP DISORDERED BREATHING; VISCERA; WEIGHT REDUCTION;

ASIAN CONTINENTAL ANCESTRY GROUP; BODY COMPOSITION; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEEDING BEHAVIOR; FEMALE; HUMANS; INSULIN RESISTANCE; JAPAN; MALE; OBESITY, ABDOMINAL; RISK ASSESSMENT; WEIGHT REDUCTION PROGRAMS;

EID: 84857731415     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339912799424546     Document Type: Article

References (109)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.
3. Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res Clin Pract 2010; 87: 15-9.
4. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010; 375: 408-18.
5. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-40.
6. Wulan SN, Westerterp KR, Plasqui G. Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians. Maturitas 2010; 65: 315-19.
7. World Health Organization. Preventing chronic diseases: a vital investment. In: WHO Fact Sheet No 311, 2005.
8. Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011; 300: G697-702.
9. Felber JP, Haesler E, Jéquier E. Metabolic origin of insulin resistance in obesity with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 1221-9.
10. Golay A, Felber JP. Evolution from obesity to diabetes. Diabet Metab 1994; 20: 3-14.
11. Felber JP, Golay A. Pathways from obesity to diabetes. Int J Obes Relat Metab Disord 2002; 26: S39-45.
12. Ohmura T, Ueda K, Kiyohara Y, et al. Prevalence of type 2 (noninsulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama Study. Diabetologia 1993; 36: 1198-203.
13. Sekikawa A, Eguchi H, Tominaga M, et al. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in a rural area of Japan. The Funagata diabetes study. J Diabetes Complications 2000; 14: 78-83.
14. Kishida K, Funahashi T, Shimomura I. Clinical significance of visceral fat reduction through health education in preventing atherosclerotic cardiovascular disease-Lesson from the Amagasaki Visceral Fat Study: A Japanese perspective. Nutr Metab (Lond) 2011; 8: 57.
15. Fujimoto WY, Akanuma Y, Kanazawa Y, Mashiko S, Leonetti D, Wahl P. Plasma insulin levels in Japanese and Japanese-American men with type 2 diabetes may be related to the occurrence of cardiovascular disease. Diabetes Res Clin Pract 1989; 6: 121-7.
16. Fujimoto WY. Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups. Diabet Med 1996; 13: S7-10.
17. Huxley R, James WP, Barzi F, et al. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev 2008; 9: 53-61.
18. Nagaya T, Yoshida H, Takahashi H, Kawai M. Increases in body mass index, even within non-obese levels, raise the risk for Type 2 diabetes mellitus: a follow-up study in a Japanese population. Diabet Med 2005; 22: 1107-11.
19. Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complication Study Group. Obesity and type 2 diabetes in Japanese patients. Lancet 2003; 361: 85.
20. Ohnishi H, Saitoh S, Takagi S, et al. Incidence of type 2 diabetes in individuals with central obesity in a rural Japanese population: The Tanno and Sobetsu study. Diabetes Care 2006; 29: 1128-9.
21. O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007; 100: 899-904.
22. Peter R, Okoseime OE, Rees A, Owens DR. Postprandial glucose-a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol 2009; 7: 68-74.
23. Lautt WW. Postprandial insulin resistance as an early predictor of cardiovascular risk. Ther Clin Risk Manag 2007; 3: 761-770.
24. Satoh H, Terada H, Uehara A, et al. Post-challenge hyperinsulinaemia rather than hyperglycaemia is associated with the severity of coronary artery disease in patients without a previous diagnosis of diabetes mellitus. Heart 2005; 91: 731-6.
25. Nakatsuji H, Kishida K, Kitamura T, Nakajima C, Funahashi T, Shimomura I. Dysregulation of glucose, insulin, triglyceride, blood pressure, and oxidative stress after an oral glucose tolerance test in men with abdominal obesity. Metabolism 2010; 59: 520-6.
26. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46: 1579-85.
27. Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab 2000; 278: E941-8
28. Smith U, Hammersten J, Björntorp P, Kral JG. Regional differences and effect of weight reduction on human fat cell metabolism. Eur J Clin Invest 1979; 9: 327-32.
29. Kuriyama H, Yamashita S, Shimomura I, et al. Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. Hepatology 1998; 27: 557-62.
30. Kuriyama H, Shimomura I, Kishida K, et al. Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. Diabetes 2002; 51: 2915-21.
31. Klein S. The case of visceral fat: argument for the defense. J Clin Invest 2004; 113: 1530-2.
32. Lettner A, Roden M. Ectopic fat and insulin resistance. Curr Diab Rep 2008; 8: 185-91.
33. Szendroedi J, Roden M. Ectopic lipids and organ function. Curr Opin Lipidol 2009; 20: 50-6.
34. Després JP. Excess visceral adipose tissue/ectopic fat the missing link in the obesity paradox? J Am Coll Cardiol 2011; 57: 1887-9.
35. Maeda K, Okubo K, Shimomura I, Mizuno K, Matsuzawa Y, Matsubara K. Analysis of an expression profile of genes in the human adipose tissue. Gene 1997; 190: 227-35.
36. Funahashi T, Nakamura T, Shimomura I, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999; 38: 202-6.
37. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-9.
38. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14: 561-6.
39. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-9.
40. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adiposespecific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-703.
41. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996; 120: 803-12.
42. Funahashi T, Matsuzawa Y. Metabolic syndrome: clinical concept and molecular basis. Ann Med 2007; 39: 482-94.
43. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
44. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975-81.
45. Okauchi Y, Kishida K, Funahashi T, et al. Changes in serum adiponectin concentrations correlate with changes in BMI, waist circumference, and estimated visceral fat area in middle-aged general population. Diabetes Care 2009; 32: e122.
46. Kishida K, Kim KK, Funahashi T, Matsuzawa Y, Kang HC, Shimomura I. Relationships between Circulating Adiponectin Levels and Fat Distribution in Obese Subjects. J Atheroscler Thromb 2011; 18: 592-5.
47. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9.
48. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-9.
49. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-804.
50. Kopp HP, Krzyzanowska K, Möhlig M, Spranger J, Pfeiffer AF, Schernthaner G. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (Lond) 2005; 29: 766-71.
51. Ng TW, Watts GF, Barrett PH, Rye KA, Chan DC. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care 2007; 30: 2945-50.
52. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-9.
53. Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-63.
54. Hiuge A, Tenenbaum A, Maeda N, et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007; 27: 635-41.
55. Hiuge-Shimizu A, Maeda N, Hirata A, et al. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone. Arterioscler Thromb Vasc Biol 2011; 31: 792-9.
56. Kurata A, Nishizawa H, Kihara S, et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717-24.
57. Derosa G, Maffioli P, Salvadeo SA, et al. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res 2010; 33: 790-5.
58. Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253-61.
59. Hirata A, Maeda N, Hiuge A, et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009; 84: 164-72.
60. Wackers FJ, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27: 1954-61.
61. Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V. Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care 1999; 22: 1396-400.
62. Valensi P, Pariès J, Brulport-Cerisier V, et al. Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study. Diabetes Care 2005; 28: 2722-7.
63. Geroulakos G, O'Gorman DJ, Kalodiki E, Sheridan DJ, Nicolaides AN. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J 1994; 15: 781-5.
64. Haller C, Schulz J, Schmidt-Trucksäss A, et al. Sequential based analysis of Intima-Media Thickness (IMT) in common carotid artery studies. Atherosclerosis 2007; 195: e203-9.
65. Thatipelli MR, Pellikka PA, McBane RD, et al. Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease. J Vasc Surg 2007; 46: 62-70.
66. Hirata A, Kishida K, Hiuge-Shimizu A, Nakatsuji H, Funahashi T, Shimomura I. Qualitative score of systemic arteriosclerosis by vascular ultrasonography as a predictor of coronary artery disease in type 2 diabetes. Atherosclerosis. 2011 in press.
67. Preston BT, Capellini I, McNamara P, Barton RA, Nunn CL. Parasite resistance and the adaptive significance of sleep. BMC Evol Biol 2009; 9: 7.
68. Resnick HE, Redline S, Shahar E, et al. Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care 2003; 26: 702-9.
69. Kawakami N, Takatsuka N, Shimizu H. Sleep disturbance and onset of type 2 diabetes. Diabetes Care 2004; 27: 282-3.
70. Buxton OM, Pavlova M, Reid EW, Wang W, Simonson DC, Adler GK. Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes 2010; 59: 2126-33.
71. Knutson KL, Van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. Ann N Y Acad Sci 2008; 1129: 287-304.
72. Tasali E, Leproult R, Ehrmann DA, Van Cauter E. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci USA 2008; 105: 1044-9.
73. Leproult R, Van Cauter E. Role of sleep and sleep loss in hormonal release and metabolism. Endocr Dev 2010; 17: 11-21.
74. Tishler PV, Larkin EK, Schluchter MD, Redline S. Incidence of sleep-disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. JAMA 2003; 289: 2230-7.
75. Kashine S, Kishida K, Funahashi T, et al. Characteristics of sleepdisordered breathing in Japanese patients with type 2 diabetes mellitus. Metabolism 2010; 59: 690-6.
76. Kashine S, Kishida K, Funahashi T, Yasuda Y, Okita K, Shimomura I. Selective contribution of waist circumference reduction on the improvement of sleep-disordered breathing in patients hospitalized with type 2 diabetes mellitus. Intern Med 2011; 50: 1895-903.
77. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994; 70: 950-3.
78. Hjartåker A, Langseth H, Weiderpass E. Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol 2008; 630: 72-93.
79. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-85.
80. Chowdhury TA. Diabetes and cancer. QJM 2010; 103: 905-15.
81. Irigaray P, Newby JA, Lacomme S, Belpomme D. Overweight/ obesity and cancer genesis: more than a biological link. Biomed Pharmacother 2007; 61: 665-78.
82. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Bodymass index and incidence of cancer: a systematic review and metaanalysis of prospective observational studies. Lancet 2008; 371: 569-78.
83. Parr CL, Batty GD, Lam TH, et al. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. Lancet Oncol 2010; 11: 741-52.
84. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132: 2208-25.
85. Ursin G, Longnecker MP, Haile RW, Greenland S. A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology 1995; 6: 137-41.
86. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000; 152: 514-27.
87. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17: 989-1003.
88. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 2007; 86: 556-65.
89. Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev 2008; 17: 352-8.
90. Kalergis M, Pacaud D, Strychar I, Meltzer S, Jones PJ, Yale JF. Optimizing insulin delivery: assessment of three strategies in intensive diabetes management. Diabetes Obes Metab 2000; 2: 299-305.
91. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 2002; 325: 746.
92. Lopes Souto D, Lopes Rosado E. Use of carb counting in the dietary treatment of diabetes mellitus. Nutr Hosp 2010; 25: 18-25.
93. Valla V. Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps. Exp Diabetes Res 2010; 2010: 178372.
94. Smith DE, Heckemeyer CM, Kratt PP, Mason DA. Motivational interviewing to improve adherence to a behavioral weight-control program for older obese women with NIDDM. A pilot study. Diabetes Care 1997; 20: 52-4.
95. Nelson SE. Management of patients with type 2 diabetes. Curr Med Res Opin 2011; 27: 1931-47.
96. McFarland MS, Brock M, Ryals C. Place in therapy for liraglutide and saxagliptin for type 2 diabetes. South Med J 2011; 104: 426-39.
97. Davies MJ, Kela R, Khunti K. Liraglutide-overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011; 13: 207-20.
98. Peacock I, Tattersall RB. The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? Br Med J (Clin Res Ed) 1984; 288: 1956-9.
99. Vessby B, Boberg M, Hellsing K, Lithell H, Berne C. C-peptide but not insulin concentrations are related to the serum lipoprotein levels during insulin treatment of non-insulin-dependent diabetes mellitus (NIDDM) patients. Diabetes Res 1989; 12: 109-16.
100. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000; 2: 105-12.
101. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175-87.
102. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-20.
103. Halford JC, Harrold JA. Neuropharmacology of human appetite expression. Dev Disabil Res Rev 2008; 14: 158-64.
104. Leombruni P, Lavagnino L, Gastaldi F, Vasile A, Fassino S. Duloxetine in obese binge eater outpatients: preliminary results from a 12-week open trial. Hum Psychopharmacol 2009; 24: 483-8.
105. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-34.
106. Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009; 13: 1-190, 215-357.
107. Horner KM, Byrne NM, Cleghorn GJ, Näslund E, King NA. The effects of weight loss strategies on gastric emptying and appetite control. Obes Rev 2011. doi: 10.1111/j.1467-789X.2011.00901.x.
108. Després JP, Couillard C, Gagnon J, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol 2000; 20: 1932-8.
109. Kadowaki T, Sekikawa A, Murata K, et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int J Obes (Lond) 2006; 30: 1163-65.